High-Throughput Dried Blood Spot (HT-DBS) Technologies in SARS COV-2 Serology and Vaccinology

项目摘要 随着COVID-19大流行继续在美国蔓延，我们必须实施 技术来筛选大面积人群中是否存在SARS-CoV-2抗体。 血清学监测不仅提供了一个衡量病毒暴露在整个社区， 提供预测疫情动态所需的信息。此外，由于我们对如何 体液因素有助于控制（并可能加剧）COVID-19， 现有的方法来测量与天然SARS-CoV- 2暴露和候选SARS-CoV-2疫苗。U 01提案旨在促进干血的使用 斑点（DBS）结合基于Luminex的微球免疫测定（MIA），以实现高通量 (HT)对SARS-CoV-2进行全人群血清学监测。具体而言，该提案将扩大HT- DBS检测用于捕获SARS-CoV-2抗体应答的广度和复杂性， 感染，并开发一种高通量竞争性免疫测定法（CIA）作为SARS替代指标- DBS中CoV-2中和抗体滴度。拟在2010年开发的拟议平台技术 沃兹沃斯中心将直接为NCI的使命做出贡献，即“. 血清学检测和相关技术.”以应对COVID-19大流行。

Project Summary As the COVID-19 pandemic continues to spread across the United States it is imperative that we implement technologies to screen large swaths of the population for the presence of antibodies to SARS-CoV-2. Serological surveillance not only affords a measure of virus exposure within a community at large but also provides information necessary to predict outbreak dynamics. Furthermore, as our understanding of how humoral factors contribute to controlling (and possibly exacerbating) COVID-19, it will be essential to have methods in place to measure the “quantity” and “quality” of antibodies associated with both natural SARS-CoV- 2 exposure and candidate SARS-CoV-2 vaccines. This U01 proposal seeks to advance the use of dried blood spots (DBS) in conjunction with a Luminex-based microsphere immunoassay (MIA) to enable high-throughput (HT) population-wide serological surveillance for SARS-CoV-2. Specifically, the proposal will expand the HT- DBS assay to capture the breadth and complexity of SARS-CoV-2 antibody responses following natural infection, and develop a high-throughput competitive immunoassay (CIA) as a surrogate measure of SARS- CoV-2 neutralizing antibody titers in DBS. The proposed platform technologies to be developed at the Wadsworth Center will contribute directly to NCI’s mission to “… develop, validate, improve and implement serological testing and associated technologies…” to address the COVID-19 pandemic.